CTI BioPharma Corp.

Find Ratings Reports
CTIC : NASDAQ :
$3.91 | %
Today's Range: 3.9 - 4.05
Avg. Daily Volume: 0
04/21/17 - 4:00 PM ET

Financial Analysis


CTI BIOPHARMA CORP's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. CTI BIOPHARMA CORP has average liquidity. Currently, the Quick Ratio is 1.29 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 74.40% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)9.1411.32
EBITDA ($mil)-11.26-25.97
EBIT ($mil)-11.46-26.2
Net Income ($mil)-6.37-25.64


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)44.0128.18
Total Assets ($mil)63.84144.33
Total Debt ($mil)19.2656.63
Equity ($mil)13.3252.03


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin-123.28-229.34
EBITDA Margin-123.28-229.33
Operating Margin-125.42-231.39
Sales Turnover0.90.11
Return on Assets-81.46-82.74
Return on Equity-390.48-235.67
Debt Q4 FY16 Q4 FY15
Current Ratio1.371.86
Debt/Capital0.590.52
Interest Expense0.630.0
Interest Coverage-18.30.0


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)28.2328.05
Div / share0.00.0
EPS-0.3-1.3
Book value / share0.471.86
Institutional Own % n/a n/a
Avg Daily Volume143861.0854650.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 8.61 indicates a significant premium versus the S&P 500 average of 2.97 and a significant discount versus the industry average of 11.90. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the industry average, indicating a discount. After reviewing these and other key valuation criteria, CTI BIOPHARMA CORP proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CTIC NM Peers 38.90   CTIC NM Peers 25.02

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CTIC's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CTIC's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CTIC NA Peers 62.56   CTIC NA Peers 0.48

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CTIC 8.61 Peers 11.90   CTIC 71.65 Peers 168.00

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CTIC is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CTIC is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CTIC 2.00 Peers 178.31   CTIC 256.19 Peers 403.70

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CTIC is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CTIC significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades